Avalglucosidase alfa (GZ402666) ( DrugBank: Avalglucosidase alfa )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
256 | 筋型糖原病 | 2 |
256. 筋型糖原病
臨床試験数 : 180 / 薬物数 : 133 - (DrugBank : 29) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 105
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05164055 (ClinicalTrials.gov) | July 11, 2022 | 16/11/2021 | Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase) | A French Multicenter Phase 4 Open Label Extension Study of Long Term Safety and Efficacy in Patients With Pompe Disease Who Previously Participated in Avalglucosidase Development Studies in France | Glycogen Storage Disease Type II | Drug: Avalglucosidase alfa (GZ402666) | Genzyme, a Sanofi Company | NULL | Recruiting | 6 Months | N/A | All | 18 | Phase 4 | France |
2 | NCT02782741 (ClinicalTrials.gov) | November 2, 2016 | 23/5/2016 | Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease | A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase Alfa in Treatment naïve Patients With Late-onset Pompe Disease | Glycogen Storage Disease Type II;Pompe's Disease | Drug: Avalglucosidase alfa (GZ402666);Drug: Alglucosidase alfa (GZ419829) | Genzyme, a Sanofi Company | NULL | Active, not recruiting | 3 Years | N/A | All | 100 | Phase 3 | United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Spain;Switzerland;Taiwan;Turkey;United Kingdom;Bulgaria;Colombia;Czech Republic;Sweden |